Whitney Reed, APRN
Psychiatric/Mental Health · Mountain Home, ARNPI 1710361464
Payments from drug & device makers
Across 96 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$400
- Teva Pharmaceuticals USA, Inc.$257
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$229
- Otsuka America Pharmaceutical, Inc.$191
- Alkermes, Inc.$160
- AbbVie$145
- plus $468 from 8 others
What the payments were for
- Food & beverage$1,62688%
- Education$22412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 18 | $400 |
| Teva Pharmaceuticals USA, Inc. | 10 | $257 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $229 |
| Otsuka America Pharmaceutical, Inc. | 11 | $191 |
| Alkermes, Inc. | 8 | $160 |
| AbbVie | 8 | $145 |
| Neurocrine Biosciences, Inc. | 7 | $116 |
| GSK | 6 | $92 |
| Lundbeck LLC | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| AstraZeneca | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $25 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$1,850 in reported general payments places this provider in the 70th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 155 | $504,377 |
| Austedo XrDeutetrabenazine | 58 | $487,496 |
| AustedoDeutetrabenazine | 59 | $345,034 |
| IngrezzaValbenazine Tosylate | 30 | $278,586 |
| Abilify MaintenaAripiprazole | 66 | $191,880 |
| AristadaAripiprazole Lauroxil | 54 | $174,276 |
| Invega TrinzaPaliperidone Palmitate | 16 | $153,565 |
| RexultiBrexpiprazole | 61 | $105,431 |
| VraylarCariprazine Hcl | 47 | $72,062 |
| CaplytaLumateperone Tosylate | 22 | $36,055 |
| LatudaLurasidone Hcl | 15 | $34,919 |
| BelsomraSuvorexant | 76 | $33,993 |
| Lurasidone Hcl | 115 | $29,615 |
| Paliperidone ErPaliperidone | 181 | $26,629 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 67 | $11,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $257 | $832,530117 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $400 | $657,942171 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $191 | $297,311127 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $116 | $278,58630 claims |
| Alkermes, Inc.Aristada | $160 | $174,27654 claims |
| AbbVieVraylar | $145 | $72,06247 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $229 | $36,05522 claims |
| Lilly USA, LLCOlanzapine | $14 | $3,377181 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Mountain Home
- Christie KellerFayetteville$167K
- Stephanie BohannonFayetteville$32K
- Michael BelinSherwood$30K
- Sarah RamseySearcy$12K
- Mallori LevengoodPine Bluff$11K
- Jennifer PenneFayetteville$11K
- Stephanie ParishSearcy$9K
- Elizabeth HardyTexarkana$8K
- Tammy HawkinsJonesboro$8K
- Cara MeckfesselLittle Rock$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.